Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer

Completed · Phase 1

Conditions studied: Melanoma, Kidney Neoplasms, Metastases

In brief

This study is being done to see if an experimental drug called recombinant interleukin-21 (rIL-21) when given to patients with stage 4 malignant melanoma or stage 4 kidney cancer is safe and has any effect on these types of cancers.

Key facts

Study ID

NCT00095108

Run by

ZymoGenetics

People needed

43

Starts

2004-05-01

Expected to finish

2007-01-01

Last updated by the study team

2009-03-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years and older with stage 4 metastatic malignant melanoma or stage 4 metastatic kidney cancer
• ECOG status of 0 or 1
• Patients must have adequate liver, kidney and bone marrow function

You may not qualify if…

• Known ocular melanoma
• Suspected or confirmed brain metastases
• Patient cannot have had a bone marrow transplant

Where it is running

• University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
• University of Washington/Seattle Cancer Care Alliance — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.